Annual Report Reveals Significant Loss Increase Amidst Key Product Approvals and Substantial Capital Raises

summarizeSummary

Ascentage Pharma reported a significant increase in net loss and a decline in revenue for 2025, but successfully raised substantial capital through a U.S. IPO and a placing, while also achieving key regulatory approvals and advancing its clinical pipeline.

check_boxKey Events

• Net Loss Surges in 2025

  The company's net loss increased by 206.4% to RMB1,243.0 million (US$177.7 million) for the fiscal year ended December 31, 2025, compared to RMB405.7 million in 2024.

• Revenue Decline Reported

  Total revenue decreased by 41.5% to RMB574.1 million (US$82.1 million) in 2025, primarily due to lower intellectual property income from a Takeda agreement in the prior year.

• Successful Capital Raises Boost Liquidity

  Ascentage Pharma raised approximately US$126.4 million gross from a U.S. IPO and US$190.1 million net from a placing in 2025, increasing cash and bank balances to US$353.2 million by year-end.

• Lisaftoclax Approved and Commercialized in China

  Lisaftoclax received NMPA approval in China for CLL/SLL in July 2025 and commenced commercial sales shortly thereafter, marking a significant pipeline advancement.

auto_awesomeAnalysis

Ascentage Pharma's annual report highlights a substantial increase in net loss for 2025, reaching RMB1,243.0 million (US$177.7 million), a 206.4% rise from the previous year. This was accompanied by a 41.5% decrease in revenue to RMB574.1 million (US$82.1 million), primarily due to lower intellectual property income from a Takeda agreement in 2024. Despite the financial setbacks and increased operating cash burn, the company significantly bolstered its liquidity through a successful U.S. IPO (US$126.4 million gross) and a placing (US$190.1 million net) in 2025, increasing cash and bank balances to US$353.2 million. This capital infusion is critical for funding ongoing and planned research and development activities. The company also achieved a major milestone with the NMPA approval and commercial launch of Lisaftoclax in China in July 2025, and secured IND clearances from both the FDA and China CDE for its novel BTK degrader, APG-3288, in early 2026, advancing it into global Phase 1 studies. The strategic partnership with Takeda, including a US$100 million upfront payment and potential US$1.2 billion in milestones, further validates its pipeline. Investors will closely monitor the company's ability to translate its pipeline advancements and commercial launches into improved financial performance and reduced losses in future periods.